Compare RDY & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | TWST |
|---|---|---|
| Founded | 1984 | 2013 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 7.9B |
| IPO Year | 2001 | 2018 |
| Metric | RDY | TWST |
|---|---|---|
| Price | $14.92 | $105.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | $14.79 | ★ $128.82 |
| AVG Volume (30 Days) | ★ 2.4M | 2.2M |
| Earning Date | 10-23-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.43% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $459,433,000.00 |
| Revenue This Year | $4.58 | $21.01 |
| Revenue Next Year | $11.95 | $18.75 |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | ★ 22.00 |
| 52 Week Low | $11.36 | $28.27 |
| 52 Week High | $15.67 | $219.71 |
| Indicator | RDY | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 68.25 | 37.96 |
| Support Level | $12.91 | $82.66 |
| Resistance Level | $15.08 | $153.47 |
| Average True Range (ATR) | 0.26 | 13.49 |
| MACD | -0.04 | -1.87 |
| Stochastic Oscillator | 78.74 | 20.48 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Twist Bioscience Corp provides customizable solutions across the biological continuum, helping customers read, write and innovate in biology. The core of its business is a proprietary platform that allows it to manufacture synthetic DNA by writing DNA on a silicon chip. The company operates as one reportable and operating segment, through which it develops, manufactures and sells DNA Synthesis and Protein Solutions and NGS Applications products and services. It has presence in Americas, EMEA, and APAC. Majority of revenue comes from Americas. Its products are Genes, Oligo Pools, NGS, Variant Libraries, Synthetic Controls, Antibody Discovery, and VDR Solutions.